Sudan Loganathan
Stock Analyst at Stephens & Co.
(3.97)
# 674
Out of 5,113 analysts
45
Total ratings
57.89%
Success rate
11.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Overweight | $95 | $72.38 | +31.25% | 1 | Dec 17, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $65 → $110 | $72.15 | +52.46% | 3 | Dec 11, 2025 | |
| CADL Candel Therapeutics | Reiterates: Overweight | $15 | $6.10 | +145.90% | 2 | Dec 8, 2025 | |
| PYXS Pyxis Oncology | Maintains: Overweight | $5 → $8 | $1.64 | +387.80% | 2 | Nov 24, 2025 | |
| IMNM Immunome | Maintains: Overweight | $25 → $33 | $25.70 | +28.40% | 3 | Nov 17, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $14 → $15 | $13.62 | +10.13% | 3 | Nov 10, 2025 | |
| DCTH Delcath Systems | Maintains: Overweight | $25 → $18 | $10.21 | +76.30% | 4 | Nov 5, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $35 | $25.99 | +34.67% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Reiterates: Overweight | $6 | $2.14 | +180.37% | 3 | Sep 22, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $45 | $34.74 | +29.53% | 3 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $19.41 | +54.56% | 4 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $60 | $43.74 | +37.17% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $33 | $24.07 | +37.10% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $3.59 | +122.84% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $15 | $7.07 | +112.16% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.29 | +287.60% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $9.94 | +906.04% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.53 | +1,207.19% | 1 | May 14, 2024 |
Apogee Therapeutics
Dec 17, 2025
Initiates: Overweight
Price Target: $95
Current: $72.38
Upside: +31.25%
Kymera Therapeutics
Dec 11, 2025
Maintains: Overweight
Price Target: $65 → $110
Current: $72.15
Upside: +52.46%
Candel Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $15
Current: $6.10
Upside: +145.90%
Pyxis Oncology
Nov 24, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $1.64
Upside: +387.80%
Immunome
Nov 17, 2025
Maintains: Overweight
Price Target: $25 → $33
Current: $25.70
Upside: +28.40%
Arvinas
Nov 10, 2025
Maintains: Overweight
Price Target: $14 → $15
Current: $13.62
Upside: +10.13%
Delcath Systems
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $18
Current: $10.21
Upside: +76.30%
Centessa Pharmaceuticals
Oct 28, 2025
Initiates: Overweight
Price Target: $35
Current: $25.99
Upside: +34.67%
C4 Therapeutics
Sep 22, 2025
Reiterates: Overweight
Price Target: $6
Current: $2.14
Upside: +180.37%
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $34.74
Upside: +29.53%
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $19.41
Upside: +54.56%
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $43.74
Upside: +37.17%
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $24.07
Upside: +37.10%
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $3.59
Upside: +122.84%
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $7.07
Upside: +112.16%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.29
Upside: +287.60%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $9.94
Upside: +906.04%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.53
Upside: +1,207.19%